Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001968202-23-000050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-12 | 2023-12-08 | REGN | Fenimore Christopher R. | SVP Ctrl | A - Grant | $0.00 | +2,370 | 22.8K | +12% | $0 |
| DM | 2023-12-12 | 2023-12-08+ | REGN | Fenimore Christopher R. | SVP Ctrl | F - Tax | $844.02 | -2,010 | 21.3K | -9% | -$1.70M |
| D | 2023-12-12 | 2023-12-08 | REGN | Fenimore Christopher R. | SVP Ctrl | A - Grant | $0.00 | +8,499 | 8,499 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-08 | A | A | 2,370 | $0.00 | 22,838 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-11 | F | D | 1,276 | $844.09 | 21,562 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-08 | F | D | 474 | $843.79 | 20,468 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-11 | F | D | 260 | $844.09 | 21,302 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-08 | A | A | 8,499 | $0.00 | 8,499 | D | $843.79 · — to 2033-12-08 | 8,499 Common Stock | (F3) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |